Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitagliptin in T2DM with Inadequate Glycemic Control
NCT00832624Phase 4Terminated
- Sponsor
- Merck & Co.
- Start
- Nov 2008
- Primary completion
- Sep 2009
- Modality
- Small Molecules
01
Overview
Phase 4, open-label, single-arm trial of sitagliptin in type 2 diabetes mellitus (T2DM), sponsored by Merck & Co. Primary endpoint: Hemoglobin A1c at Week 18. Started Nov 2008; status: terminated.
02
Drugs
sitagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00832624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00832624.